Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

MeSH terms

• Antibodies, Monoclonal, Humanized / adverse effects
• Antibodies, Monoclonal, Humanized / therapeutic use*
• Clinical Trials, Phase III as Topic
• Double-Blind Method
• Humans
• Metabolic Syndrome / complications
• Psoriasis / complications
• Psoriasis / drug therapy*
• Randomized Controlled Trials as Topic
• Treatment Outcome